Patients who are at significant risk of an embolic event (eg, patients who have history of pulmonary embolism or atrial fibrillation with history of stroke) are given a short-acting anticoagulant such as low molecular weight heparin after stopping warfarin (called bridging anticoagulation—see Deep Venous Thrombosis).